Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cu-67 SARTATE in Meningioma
NCT03936426Phase 2Completed
- Sponsor
- Clarity Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Sep 2019
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 67Cu-SARTATE in meningioma, sponsored by Clarity Pharmaceuticals. Primary endpoints: Safety and tolerability of multiple doses of Cu-67 SARTATE at 55 weeks and Safety and tolerability of a single dose of Cu-64 SARTATE at 56 weeks. Started Jul 2018; status: completed.
02
Drugs
67Cu-SARTATE
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT03936426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936426.